Lynne T Haber

List of Publications by Year
in descending order

46 papers	1,490 citations	361045 20 h-index	329751 37 g-index
51 all docs	51 docs citations	51 times ranked	1979 citing authors

#	Article	IF	Citations
1	Copper and Human Health: Biochemistry, Genetics, and Strategies for Modeling Dose-response Relationships. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2007, 10, 157-222.	2.9	276
2	Benchmark dose (BMD) modeling: current practice, issues, and challenges. Critical Reviews in Toxicology, 2018, 48, 387-415.	1.9	131
3	Linear low-dose extrapolation for noncancer health effects is the exception, not the rule. Critical Reviews in Toxicology, 2011, 41, 1-19.	1.9	108
4	Hazard Identification and Dose Response of Inhaled Nickel-Soluble Salts. Regulatory Toxicology and Pharmacology, 2000, 31, 210-230.	1.3	102
5	Meta-regression analysis of the effects of dietary cholesterol intake on LDL and HDL cholesterol. American Journal of Clinical Nutrition, 2019, 109, 7-16.	2.2	65
6	Genetic Polymorphisms in Assessing Interindividual Variability in Delivered Dose. Regulatory Toxicology and Pharmacology, 2002, 35, 177-197.	1.3	55
7	An Approach for the Quantitative Consideration of Genetic Polymorphism Data in Chemical Risk Assessment: Examples with Warfarin and Parathion. Toxicological Sciences, 2002, 70, 120-139.	1.4	51
8	Human relevance of rodent liver tumors: Key insights from a Toxicology Forum workshop on nongenotoxic modes of action. Regulatory Toxicology and Pharmacology, 2018, 92, 1-7.	1.3	50
9	Advancing human health risk assessment: Integrating recent advisory committee recommendations. Critical Reviews in Toxicology, 2013, 43, 467-492.	1.9	42
10	Confirmation of an acute no-observed-adverse-effect and low-observed-adverse-effect level for copper in bottled drinking water in a multi-site international study. Regulatory Toxicology and Pharmacology, 2003, 38, 389-399.	1.3	39
11	Evidence-based doseâ€“response assessment for thyroid tumorigenesis from acrylamide. Regulatory Toxicology and Pharmacology, 2008, 52, 264-289.	1.3	36
12	Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats. Regulatory Toxicology and Pharmacology, 2015, 73, 151-163.	1.3	33
13	Systems Biology and Biomarkers of Early Effects for Occupational Exposure Limit Setting. Journal of Occupational and Environmental Hygiene, 2015, 12, S41-S54.	0.4	31
14	Derivation of an oral toxicity reference value for nickel. Regulatory Toxicology and Pharmacology, 2017, 87, S1-S18.	1.3	31
15	A Bayesian Network Model for Biomarker-Based Dose Response. Risk Analysis, 2010, 30, 1037-1051.	1.5	29
16	Impact of Chemical Proportions on the Acute Neurotoxicity of a Mixture of Seven Carbamates in Preweanling and Adult Rats. Toxicological Sciences, 2012, 129, 126-134.	1.4	27
17	Analysis of in vivo mutation data can inform cancer risk assessment. Regulatory Toxicology and Pharmacology, 2008, 51, 151-161.	1.3	26
18	Scientific Criteria Used for the Development of Occupational Exposure Limits for Metals and Other Mining-Related Chemicals. Regulatory Toxicology and Pharmacology, 2002, 36, 262-279.	1.3	25

#	Article	IF	Citations
19	Evaluation of concentrationâ€“response options for diacetyl in support of occupational risk assessment. Regulatory Toxicology and Pharmacology, 2010, 58, 285-296.	1.3	24
20	Hazard Identification and Dose Response of Ingested Nickel-Soluble Salts. Regulatory Toxicology and Pharmacology, 2000, 31, 231-241.	1.3	23
21	Non-Cancer Risk Assessment for Nickel Compounds: Issues Associated with Dose-Response Modeling of Inhalation and Oral Exposures. Toxicological Sciences, 1998, 43, 213-229.	1.4	22
22	Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide. Toxicological Sciences, 2013, 136, 26-38.	1.4	22
23	A four-step approach to evaluate mixtures for consistency with dose addition. Toxicology, 2013, 313, 134-144.	2.0	21
24	Critical review of doseâ€“response options for F344 rat mammary tumors for acrylamide â€“ Additional insights based on mode of action. Food and Chemical Toxicology, 2012, 50, 1763-1775.	1.8	18
25	Data considerations for regulation of water contaminants. Toxicology, 2006, 221, 217-224.	2.0	17
26	Evaluation of human relevance and mode of action for tunica vaginalis mesotheliomas resulting from oral exposure to acrylamide. Regulatory Toxicology and Pharmacology, 2009, 53, 134-149.	1.3	16
27	Advancing Risk Analysis for Nanoscale Materials: Report from an International Workshop on the Role of Alternative Testing Strategies for Advancement. Risk Analysis, 2016, 36, 1520-1537.	1.5	16
28	Incorporation of Pharmacokinetic and Pharmacodynamic Data into Risk Assessments. Toxicology Mechanisms and Methods, 2004, 14, 145-158.	1.3	15
29	A framework for fit-for-purpose dose response assessment. Regulatory Toxicology and Pharmacology, 2013, 66, 234-240.	1.3	14
30	Meta-regression analysis of the effect of trans fatty acids on low-density lipoprotein cholesterol. Food and Chemical Toxicology, 2016, 98, 295-307.	1.8	14
31	Assessing Biomarker use in Risk Assessmentâ€”A Survey of Practitioners. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2004, 67, 687-695.	1.1	12
32	Evaluation of cII mutations in lung of male Big Blue mice exposed by inhalation to vanadium pentoxide for up to 8 weeks. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2015, 789-790, 46-52.	0.9	11
33	Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2015, 789-790, 53-60.	0.9	10
34	Dose and temporal evaluation of ethylene oxideâ€induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations. Environmental and Molecular Mutagenesis, 2017, 58, 122-134.	0.9	10
35	Framework for human health risk assessment of nonâ€cancer effects resulting from shortâ€duration and intermittent exposures to chemicals. Journal of Applied Toxicology, 2016, 36, 1077-1089.	1.4	9
36	Improving Risk Assessment: Research Opportunities in Dose Response Modeling to Improve Risk Assessment. Human and Ecological Risk Assessment (HERA), 2002, 8, 1421-1444.	1.7	7

#	Article	IF	Citations
37	Cholinesterase inhibition and depression of the photic after discharge of flash evoked potentials following acute or repeated exposures to a mixture of carbaryl and propoxur. NeuroToxicology, 2012, 33, 332-346.	1.4	7
38	Application of Markov chain Monte Carlo analysis to biomathematical modeling of respirable dust in US and UK coal miners. Regulatory Toxicology and Pharmacology, 2013, 66, 47-58.	1.3	7
39	Non-Cancer Risk Assessment for Nickel Compounds: Issues Associated with Doseâ€"Response Modeling of Inhalation and Oral Exposures,. Toxicological Sciences, 1998, 43, 213-229.	1.4	5
40	Using Best Science in Cancer Risk Assessment. Human and Ecological Risk Assessment (HERA), 2006, 12, 1-8.	1.7	4
41	Improving Risk Assessment: Toxicological Research Needs. Human and Ecological Risk Assessment (HERA), 2002, 8, 1405-1419.	1.7	3
42	Mode-of-action evaluation for the effect of trans fatty acids on low-density lipoprotein cholesterol. Food and Chemical Toxicology, 2016, 98, 282-294.	1.8	3
43	Impact of updated BMD modeling methods on perchlorate and chlorate assessments of human health hazard. Toxicology Letters, 2021, 340, 89-100.	0.4	3
44	Bayesian hierarchical evaluation of dose-response for peanut allergy in clinical trial screening. Food and Chemical Toxicology, 2021, 151, 112125.	1.8	3
45	Quantitative Modeling in Noncancer Risk Assessment. , 0, , 371-398.		3
46	Views on Key Issues Facing the Chemical Industry. , 2005, , 27-88.		0